# The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

> **NCT05284851** · PHASE2 · UNKNOWN · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 2520 (estimated)

## Conditions studied

- Influenza Prevention

## Interventions

- **BIOLOGICAL:** Live Attenuated Influenza Vaccine(non freeze-dried)
- **BIOLOGICAL:** Live Attenuated Influenza Vaccine(freeze-dried)
- **BIOLOGICAL:** Live Attenuated Influenza Vaccine placebo

## Key facts

- **NCT ID:** NCT05284851
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 2520 (ESTIMATED)
- **Last updated:** 2022-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05284851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05284851, "The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05284851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*